Case: Apotex Inc. v. Schering Corporation (Court File No. CV-11-429541)
Drug: ALTACE® (ramipril)
Nature of case: Motion to strike claims under the under the Trade-marks Act, R.S.C. 1985, c. T-13 (Trade-marks Act), the Ontario Monopolies Act (An Act concerning Monopolies and Dispensation with Penal Laws, etc., R.S.O. 1897, c. 323) and the U.K. Monopolies Act (An Act concerning Monopolies and Dispensation with Penal Laws and the Forfeitures thereof, 1624, 21 Jac. 1, c. 3)(together, Monopolies Acts).
Successful party: Apotex Inc.
Date of decision: 27 May, 2016
Summary
Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH, and
Sanofi-Aventis Canada Inc. (Sanofi) market the
drug ramipril in Canada under the name ALTACE. Sanofi sells ALTACE
under licence from Schering Corp. (Schering, and
together with Sanofi, the Defendants), which owns
various patents relating to ramipril, including the one at issue in
this case, Canadian Patent No. 1,341,206 (206
Patent). Apotex Inc. (Apotex) has sold
generic ramipril since January 2007. Apotex entered the market
after succeeding in applications before the Federal Court (the
Applications) under the Patented Medicines
(Notice of Compliance) Regulations
(Regulations). Apotex was subsequently
awarded damages under section 8 of the Regulations.
In 2009, after the Defendants brought a separate action for
infringement of the 206 Patent, Apotex succeeded in its
counterclaim, and the Court declared the 206 Patent invalid.
Despite having received compensation under s. 8 of the Regulations,
Apotex brought an action in the Ontario Superior Court claiming
further monetary remedies resulting from novel causes of action.
Specifically, it claims that by listing a patent on the Patent
Register that was later declared void, the Defendants are liable
under the Monopolies Acts and Trade-marks
Act.
The Defendants moved to strike Apotex's claims. The motion was
dismissed: Justice Dunphy held that the law surrounding these novel
issues is insufficiently settled to make it plain and obvious that
Apotex's claims would fail.
Not plain and obvious that a section 8 damages award bars other remedies
The Defendants argued that the Regulations are a
"complete code". According to the Defendants, Apotex,
which has already received the full remedy contemplated under the
Regulations, is precluded from making further claims for
relief arising outside the Regulations. Dunphy J. reviewed
the jurisprudence on this issue. Despite a recent decision of the
British Columbia Court of Appeal confirming that the
Regulations are a "complete code" (Low v. Pfizer Canada Inc., 2015 BCCA
506), he held that the law is insufficiently settled to decide the
issue at the pleadings stage.
The Defendants also asserted that the matter of compensation is
res judicata, as it was already decided in the section 8
action. Dunphy J. also refused to strike these claims, noting that
the causes of action have different triggers: the section 8 claims
arise from the Defendants' decision to commence prohibition
applications, whereas the Trade-marks Act claims are
triggered by the decision to list a patent on the Patent Register.
Accordingly, Dunphy J. believed the determination of the issue was
better left for trial.
Monopolies Acts claims not plainly deficient
The Defendants argued that the Monopolies Acts claims should be struck on several bases, including that the U.K. Monopolies Act was mostly repealed by the Ontario Monopolies Act, and that the Ontario Monopolies Act is unconstitutional. Dunphy J., citing on his decision in Apotex Inc. v. Eli Lilly and Company et al., 2015 ONSC 5396, again held that the law is not sufficiently settled to strike these claims.
Push to Trial
Despite Dunphy J's reluctance to strike Apotex's novel claims at the pleadings stage, he expressed an intent to move the action more quickly toward a resolution on the merits so that Apotex's novel claims can be determined, thereby providing much needed legal certainty.
Link:
Apotex Inc. v. Schering Corporation, 2016 ONSC 3407
About Norton Rose Fulbright Canada LLP
Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.
Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.
Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.
For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.
Law around the world
nortonrosefulbright.com
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.